183 filings
Page 5 of 10
8-K/A
lihs45gl
19 Jun 20
KemPharm Issues Letter to Shareholders
12:00am
8-K
vjdz zfj4k92py5lq4
18 Jun 20
KemPharm Issues Letter to Shareholders
9:02am
8-K
v1h5lepppwjq
20 May 20
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
8:26am
8-K
efyyeoopwodrmqo
12 May 20
KemPharm Reports First Quarter 2020 Financial Results
4:57pm
8-K
kjhsmku22
4 May 20
Regulation FD Disclosure
8:05am
8-K
vuu 8ezd4
13 Apr 20
Other Events
4:23pm
8-K
fual5hs
2 Apr 20
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5:15pm
8-K
d6t7i1tvdkk82
2 Mar 20
KemPharm Submits KP415 NDA to the FDA for the Treatment of ADHD
4:21pm
8-K
6kqjoc nkwkhkoib
28 Feb 20
KemPharm Reports Fourth Quarter and Full-Year 2019 Financial Results
7:34am
8-K
rc4v78e
18 Feb 20
Entry into a Material Definitive Agreement
6:39am
8-K
ccx0bw xdnw
10 Feb 20
Departure of Directors or Certain Officers
5:18pm
8-K
riuwwj9l4t myhyyxg
16 Jan 20
Nasdaq Grants KemPharm’s Request for Extension to Comply with the Market Value of Listed Securities Continued Listing Requirement
12:00am
8-K
62dtqyv
13 Jan 20
Entry into a Material Definitive Agreement
6:19am
8-K
m0gw9 wrcvmntf8vy
10 Jan 20
Unregistered Sales of Equity Securities
5:12pm
8-K
axr 1fn6t
31 Dec 19
Unregistered Sales of Equity Securities
8:20am
8-K
jku d423j
23 Dec 19
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:31pm
8-K
8lt0srzkm v1e7b3
18 Dec 19
KemPharm Announces Debt Restructuring with Deerfield and Delaware Street Capital
7:30am
8-K
y4xyvlrehcrbzqat94iv
21 Nov 19
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5:15pm
8-K
5ujkk
14 Nov 19
KemPharm Reports Third Quarter 2019 Results
5:22pm
8-K
vhsp0dsomq
31 Oct 19
Other Events
8:34am